The level of expression of HPV16 early transcripts is not associated with the natural history of cervical lesions.
HPV
cervical cancer
early transcript
quantification
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
06
08
2024
received:
03
06
2024
accepted:
10
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
ppublish
Résumé
The natural history of cervical cancer is closely linked to that of high-risk human papillomaviruses (HPV) infection. It is recognized that upon HPV DNA integration, partial or complete loss of the E2 open reading frame precludes expression of the corresponding protein, resulting in upregulation of the E6 and E7 viral oncoproteins. To better characterize HPV16 infection at the cervical level, viral load, viral DNA integration, and viral early transcript expression (E2, E5, and E6) were analyzed in a series of 158 cervical specimens representative of the full spectrum of cervical disease. Overall, the frequency of early transcript detection varied from 45% to 90% and tended to increase with lesion severity. In addition, the levels of E2, E5, and E6 transcript expression were slightly higher in high-grade lesions than in cervical specimens without abnormalities. Notably, early transcript expression was clearly associated with viral load, and no inverse correlation was found between the expression of E2 and E6 transcripts. No clear association was found between early transcript expression and HPV16 DNA integration, with the exception that samples with a fully integrated HPV16 genome did not harbor E2 or E5 transcripts. In conclusion, early HPV16 transcript expression appears to be associated with viral load rather than lesion grade. From a practical point of view, quantification of HPV16 early transcripts is difficult to translate into a relevant biomarker for cervical cancer screening.
Substances chimiques
Oncogene Proteins, Viral
0
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29875Subventions
Organisme : AFFDU
Organisme : Université de Franche-Comté
Organisme : Ligue Contre le Cancer
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
McLaughlin‐Drubin ME, Münger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009;143(2):195‐208. doi:10.1016/j.virusres.2009.06.008
Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086. doi:10.1038/nrdp.2016.86
Münger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus‐induced oncogenesis. J Virol. 2004;78(21):11451‐11460. doi:10.1128/JVI.78.21.11451-11460.2004
Bouvard V, Baan R, Straif K, et al. A review of human carcinogens‐‐part B: biological agents. Lancet Oncol. 2009;10(4):321‐322.
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664‐670. doi:10.1002/ijc.30716
Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(suppl 3):S42‐S51. doi:10.1016/j.vaccine.2006.06.018
Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11‐22. doi:10.1038/nrc2050
Demarco M, Hyun N, Carter‐Pokras O, et al. A study of type‐specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293. doi:10.1016/j.eclinm.2020.100293
Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10‐year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type‐specific HPV testing in clinical practice. JNCI: Journal of the National Cancer Institute. 2005;97(14):1072‐1079. doi:10.1093/jnci/dji187
Carcopino X, Henry M, Mancini J, et al. Two years outcome of women infected with high risk HPV having normal colposcopy following low‐grade or equivocal cytological abnormalities: are HPV16 and 18 viral load clinically useful predictive markers? J Med Virol. 2012;84(6):964‐972. doi:10.1002/jmv.23276
Ramanakumar AV, Goncalves O, Richardson H, et al. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV‐16 integration in persistent and transient infections in young women. BMC Infect Dis. 2010;10:326. doi:10.1186/1471-2334-10-326
Trevisan A, Schlecht NF, Ramanakumar AV, Villa LL, Franco EL. Human papillomavirus type 16 viral load measurement as a predictor of infection clearance. J Gen Virol. 2013;94(Pt 8):1850‐1857. doi:10.1099/vir.0.051722-0
van Duin M, Snijders PJF, Schrijnemakers HFJ, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer. 2002;98(4):590‐595.
Baumann A, Henriques J, Selmani Z, et al. HPV16 load is a potential biomarker to predict risk of High‐Grade cervical lesions in High‐Risk HPV‐Infected women: A large longitudinal French Hospital‐Based cohort study. Cancers. 2021;13(16):4149. doi:10.3390/cancers13164149
Depuydt CE, Criel AM, Benoy IH, Arbyn M, Vereecken AJ, Bogers JJ. Changes in type‐specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med. 2012;16(12):3096‐3104. doi:10.1111/j.1582-4934.2012.01631.x
Marks M, Gravitt PE, Utaipat U, et al. Kinetics of DNA load predict HPV 16 viral clearance. J Clin Virol. 2011;51(1):44‐49. doi:10.1016/j.jcv.2011.01.011
Monnier‐Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV‐associated lesions. J Clin Virol. 2006;35(3):270‐277. doi:10.1016/j.jcv.2005.09.001
Boulet GAV, Benoy IH, Depuydt CE, et al. Human papillomavirus 16 load and E2/E6 ratio in HPV16‐Positive women: biomarkers for cervical intraepithelial neoplasia ≥2 in a Liquid‐Based cytology setting? Cancer Epidemiol Biomarkers Prevent. 2009;18(11):2992‐2999. doi:10.1158/1055-9965.EPI-09-0025
Broccolo F, Fusetti L, Rosini S, et al. Comparison of oncogenic HPV type‐specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study. J Med Virol. 2013;85(3):472‐482. doi:10.1002/jmv.23487
Carcopino X, Henry M, Mancini J, et al. Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol. 2012;84(2):306‐313. doi:10.1002/jmv.23190
Carcopino X, Henry M, Benmoura D, et al. Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. J Med Virol. 2006;78(8):1131‐1140. doi:10.1002/jmv.20673
Cricca M, Morselli‐Labate AM, Venturoli S, et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high‐grade cervical lesions. Gynecol Oncol. 2007;106(3):549‐557. doi:10.1016/j.ygyno.2007.05.004
Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006;66(20):10112‐10119. doi:10.1158/0008-5472.CAN-06-1812
Saunier M, Monnier‐Benoit S, Mauny F, et al. Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16‐infected women with high‐grade lesions or cervical carcinoma. J Clin Microbiol. 2008;46(11):3678‐3685. doi:10.1128/JCM.01212-08
Swan DC, Tucker RA, Tortolero‐Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 1999;37(4):1030‐1034.
Tsai HT, Wu CH, Lai HL, et al. Association between quantitative high‐risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prevent. 2005;14(11 Pt 1):2544‐2549. doi:10.1158/1055-9965.EPI-05-0240
Arbyn M, Simon M, de Sanjosé S, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta‐analysis. Lancet Oncol. 2022;23(7):950‐960. doi:10.1016/S1470-2045(22)00294-7
Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC‐US or LSIL cervical cytology: a meta‐analysis of the diagnostic accuracy. Int J Cancer. 2013;132(1):101‐108. doi:10.1002/ijc.27636
Castle PE, Dockter J, Giachetti C, et al. A cross‐sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res. 2007;13(9):2599‐2605. doi:10.1158/1078-0432.CCR-06-2881
Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol Oncol. 2011;120(1):89‐93. doi:10.1016/j.ygyno.2010.09.013
Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: A cross‐sectional study of 4,136 women >30 years of age with a 2‐Year follow‐up of High‐Grade squamous intraepithelial lesion. Cancer Epidemiol Biomar Prevent. 2005;14(2):367‐372. doi:10.1158/1055-9965.EPI-04-0410
Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129(3):691‐701. doi:10.1002/ijc.25726
Pierry D, Weiss G, Lack B, Chen V, Fusco J. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than papanicolaou screening for women regardless of age. Arch Pathol Lab Med. 2012;136(8):956‐960. doi:10.5858/arpa.2011-0180-OA
Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as hybrid capture 2 assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49(2):557‐564. doi:10.1128/JCM.02147-10
Reid JL, Wright TC, Stoler MH, et al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening. Am J Clin Path. 2015;144(3):473‐483. doi:10.1309/AJCPHVD7MIP3FYVV
Spathis A, Kottaridi C, Chranioti A, et al. mRNA and DNA detection of human papillomaviruses in women of all ages attending two colposcopy clinics. PLoS One. 2012;7(11):e49205. doi:10.1371/journal.pone.0049205
Stoler MH, Wright TC, Cuzick J, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol. 2013;208(2):144.e1‐144.e8. doi:10.1016/j.ajog.2012.12.003
Waldstrøm M, Ørnskov D. Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3‐year‐old PreservCyt samples with low‐grade squamous intraepithelial lesion. Arch Pathol Lab Med. 2011;135(8):1052‐1056. doi:10.5858/2010-0411-OAR
Antonishyn NA, Horsman GB, Kelln RA, Severini A. Human papillomavirus typing and viral gene expression analysis for the triage of women with abnormal results from papanicolaou test smears to colposcopy. Arch Pathol Lab Med. 2009;133(10):1577‐1586. doi:10.5858/133.10.1577
Ho CM, Lee BH, Chang SF, et al. Type‐specific human papillomavirus oncogene messenger RNA levels correlate with the severity of cervical neoplasia. Int J Cancer. 2010;127(3):622‐632. doi:10.1002/ijc.25078
Wang‐Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep papanicolaou tests using real‐time polymerase chain reaction analysis. Cancer. 2002;94(8):2199‐2210. doi:10.1002/cncr.10439
Giorgi Rossi P, Ronco G, Mancuso P, et al. Performance of HPV E6/E7 mRNA assay as primary screening test: results from the NTCC2 trial. Int J Cancer. 2022;151(7):1047‐1058. doi:10.1002/ijc.34120
Lie AK, Risberg B, Borge B, et al. DNA‐ versus RNA‐based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol. 2005;97(3):908‐915. doi:10.1016/j.ygyno.2005.02.026
Meznad K, Paget‐Bailly P, Jacquin E, et al. The exon junction complex core factor eIF4A3 is a key regulator of HPV16 gene expression. Biosci Rep. 2021;41(4):BSR20203488. doi:10.1042/BSR20203488
Briolat J, Dalstein V, Saunier M, et al. HPV prevalence, viral load and physical state of HPV‐16 in cervical smears of patients with different grades of CIN. Int J Cancer. 2007;121(10):2198‐2204. doi:10.1002/ijc.22959
Jacquin É, Guenat D, Riethmuller D, Mougin C, Prétet JL. Nouveaux biomarqueurs viraux des lésions du col de l'utérus associées aux papillomavirus humains. Virologie (Montrouge, France). 2014;18(4):211‐228. doi:10.1684/vir.2014.0571
Rosty C, Sheffer M, Tsafrir D, et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene. 2005;24(47):7094‐7104. doi:10.1038/sj.onc.1208854
Hong D, Liu J, Hu Y, et al. Viral E6 is overexpressed via high viral load in invasive cervical cancer with episomal HPV16. BMC Cancer. 2017;17(1):136. doi:10.1186/s12885-017-3124-9
Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real‐time PCR technique. J Clin Microbiol. 2002;40(3):886‐891. doi:10.1128/jcm.40.3.886-891.2002
Häfner N, Driesch C, Gajda M, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene. 2008;27(11):1610‐1617. doi:10.1038/sj.onc.1210791
Shen Z, Liu X, Morihara J, et al. Detection of human papillomavirus infections at the Single‐Cell level. Intervirology. 2015;58(5):324‐331. doi:10.1159/000442573
Noji N, Okayama K, Oda M, Shimada A, Okodo M. Human papillomavirus infection status of single cells isolated from cervical cytology specimens by simple manual microdissection. J Med Virol. 2021;93(8):5084‐5094. doi:10.1002/jmv.26888
Okayama K, Kakinuma M, Tajima S, et al. Optimal papanicolaou smear conditions for manual microdissection of single target cells. Microorganisms. 2023;11(11):2700. doi:10.3390/microorganisms11112700
Li Y, Wang C, Ma A, et al. Identification of HPV oncogene and host cell differentiation associated cellular heterogeneity in cervical cancer via single‐cell transcriptomic analysis. J Med Virol. 2023;95(8):e29060. doi:10.1002/jmv.29060
Guo C, Qu X, Tang X, et al. Spatiotemporally deciphering the mysterious mechanism of persistent HPV‐induced malignant transition and immune remodelling from HPV‐infected normal cervix, precancer to cervical cancer: integrating single‐cell RNA‐sequencing and spatial transcriptome. Clin Transl Med. 2023;13(3):e1219. doi:10.1002/ctm2.1219